ArticleJournal of Cancer2020

Outcomes of Adjuvant Oral versus Intravenous Fluoropyrimidines for High-Risk Stage II or Stage III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study.

Jiaqiang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.